Drawing for ACCELERA PART OF NMS GROUP

USPTO serial 79325436

ACCELERA PART OF NMS GROUP

Reviewed by CopyMark Law Group

Reg. 6945266Status 700Registered
Filing date
Status date
Registration date
Jan 10, 2023
Examiner
KAPLAN, VALERIE ELIZABETH
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with ACCELERA PART OF NMS GROUP?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Jeffrey B. Sladkus, Esq.

Jeffrey B. Sladkus, Esq. The Sladkus Law Group1397 Carroll DriveAtlanta, GA 30318UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
042Scientific, technological, analysis and research services, namely, research and development in the field of medicine, specifically, testing in the field of pharmaceuticals and gene-based drugs and therapies; biological research in the field of medicine, specifically, testing in the field of pharmaceuticals and gene-based drugs and therapies; chemical research in the field of medicine, specifically, testing in the field of pharmaceuticals and gene-based drugs and therapies; Scientific research in the nature of conducting clinical trials in the field of medicine, specifically, testing in the field of pharmaceuticals and gene-based drugs and therapies; quality control in the field of medicine, product testing in the field of pharmaceuticals and gene-based drugs and therapies; scientific laboratory servicesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Nov 1, 2024NREPNEW REPRESENTATIVE AT IB RECEIVED—
May 17, 2023FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Apr 25, 2023FICSFINAL DISPOSITION NOTICE SENT TO IB—
Apr 24, 2023FIMPFINAL DISPOSITION PROCESSED—
Apr 10, 2023FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Jan 10, 2023NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Jan 10, 2023R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Oct 25, 2022NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Oct 25, 2022PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Oct 5, 2022NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Sep 19, 2022CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Sep 17, 2022TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Sep 16, 2022CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Sep 16, 2022TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 12, 2022CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Sep 12, 2022TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Sep 12, 2022ECDRTEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS—
Sep 12, 2022ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 12, 2022REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Sep 12, 2022COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Jun 6, 2022RFNTREFUSAL PROCESSED BY IB—
May 19, 2022RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
May 19, 2022RFRRREFUSAL PROCESSED BY MPU—
Apr 9, 2022RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Apr 8, 2022CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 29, 2022DOCKASSIGNED TO EXAMINER—
Nov 19, 2021MAFRAPPLICATION FILING RECEIPT MAILED—
Nov 15, 2021NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Nov 11, 2021REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance